tiprankstipranks
Trending News
More News >
ZeroStack (ZSTK)
NASDAQ:ZSTK
US Market

ZeroStack (ZSTK) AI Stock Analysis

Compare
319 Followers

Top Page

ZSTK

ZeroStack

(NASDAQ:ZSTK)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 5.2)
Rating:46Neutral
Price Target:
$7.00
▼(-0.85% Downside)
Action:ReiteratedDate:02/28/26
The score is primarily held down by weak financial performance: sharp revenue decline, ongoing losses, persistent negative free cash flow, and a significant 2025 increase in debt. Technicals are mixed with neutral momentum but a weak longer-term trend, while valuation offers limited support given the negative P/E and no dividend yield.
Positive Factors
Improving gross margin
A meaningful gross margin improvement in 2025 indicates the business achieved better unit economics or cost control. Sustained margin gains can compound profitability over time, helping absorb fixed costs and shortening the path to operating break-even if revenue stabilizes or returns to growth.
Positive equity buffer
Maintaining positive equity provides a capital buffer that reduces immediate insolvency risk and preserves financial flexibility. This structural strength supports the ability to absorb losses, negotiate financing, and pursue restructuring or strategic initiatives without immediate dilution or distress financing.
Narrowing losses and improved free cash flow
Progress toward smaller operating losses and an improving free cash flow trend is a durable sign the company is reducing cash burn. Continued improvement can lower funding needs, extend runway, and make it easier to reach positive operating cash flow, improving long-term solvency.
Negative Factors
Sharp revenue contraction
A sustained, sharp revenue decline erodes scale and undermines competitive position. Lower top-line volumes reduce operating leverage, pressure margins, and make it harder to cover fixed costs, increasing the time and investment needed to restore sustainable profitability.
Persistent negative operating and free cash flow
Continuous negative operating and free cash flow forces reliance on external financing and heightens refinancing risk. This structural cash deficit limits the company’s ability to reinvest, pursue growth initiatives, or absorb shocks without raising capital, diluting long-term shareholder value.
Dramatic debt increase in 2025
A sharp step-up in debt raises leverage and interest burden, reducing financial flexibility. Higher leverage increases covenant and refinancing risks, and limits strategic options during downturns; if cash generation remains weak, higher debt materially elevates default risk.

ZeroStack (ZSTK) vs. SPDR S&P 500 ETF (SPY)

ZeroStack Business Overview & Revenue Model

Company DescriptionZeroStack Corp. operates as an AI-powered asset management company focused on providing decentralized AI. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the $0G ecosystem and across the wider AI landscape.
How the Company Makes MoneyFlora Growth generates revenue primarily through the sale of its cannabis and hemp-derived products. The company has multiple revenue streams, including wholesale distribution to retailers, direct-to-consumer sales through e-commerce platforms, and partnerships with other brands for co-branded product lines. Additionally, Flora Growth benefits from its cultivation operations, which enable cost-effective production of high-quality cannabis. Strategic partnerships with established brands and retailers further enhance its market reach and contribute to its earnings. The company also explores opportunities in the international market, which may provide additional revenue avenues.

ZeroStack Financial Statement Overview

Summary
Revenue contraction in 2024–2025 and persistent operating/net losses weigh heavily. While losses narrowed and gross margin improved in 2025, operating and free cash flow remain negative, and the sharp 2025 debt increase raises funding and flexibility risk.
Income Statement
18
Very Negative
Revenue has been highly volatile: after strong expansion in 2021–2023, it declined in 2024 and then fell sharply again in 2025, signaling a major contraction in the business. Profitability remains weak across the period with consistent operating and net losses; however, the magnitude of losses improved substantially in 2025 versus 2023–2024. Gross margin improved meaningfully in 2025, but the company is still not close to break-even at the operating or net level.
Balance Sheet
34
Negative
The capital structure has weakened: total debt increased dramatically in 2025 and leverage moved higher, though it remains below equity in the latest year. Equity is still positive, but returns to shareholders are negative due to ongoing losses. Overall, the balance sheet shows some capacity to absorb losses, but the sharp step-up in debt increases financial risk and reduces flexibility.
Cash Flow
22
Negative
Cash generation remains a key issue with negative operating cash flow and negative free cash flow every year shown. Free cash flow improved in 2025 versus 2024, but the business is still consuming cash rather than producing it. While cash burn has moderated at times, the lack of sustained positive operating cash flow keeps funding risk elevated, especially alongside the recent increase in leverage.
BreakdownDec 2025Dec 2024Dec 2023Mar 2023Mar 2022
Income Statement
Total Revenue35.68M59.51M76.07M33.40M8.98M
Gross Profit6.29M12.50M17.74M13.25M2.42M
EBITDA-8.98M-15.10M-45.87M-17.87M-20.93M
Net Income-120.85M-15.91M-57.04M-52.41M-21.25M
Balance Sheet
Total Assets130.24M26.23M23.63M80.99M85.48M
Cash, Cash Equivalents and Short-Term Investments5.60M6.02M4.35M8.94M37.61M
Total Debt53.93M4.90M3.67M3.76M1.34M
Total Liabilities59.68M21.72M17.22M24.57M8.54M
Stockholders Equity70.55M4.51M6.40M56.82M77.17M
Cash Flow
Free Cash Flow-8.80M-5.17M-8.56M-17.23M-24.63M
Operating Cash Flow-8.68M-5.03M-8.40M-15.94M-20.65M
Investing Cash Flow-3.46M203.00K-234.00K-15.80M-14.55M
Financing Cash Flow11.35M6.49M3.15M4.41M58.11M

ZeroStack Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.06
Price Trends
50DMA
7.96
Negative
100DMA
9.61
Negative
200DMA
16.78
Negative
Market Momentum
MACD
-0.09
Positive
RSI
42.62
Neutral
STOCH
2.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZSTK, the sentiment is Negative. The current price of 7.06 is below the 20-day moving average (MA) of 8.69, below the 50-day MA of 7.96, and below the 200-day MA of 16.78, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.62 is Neutral, neither overbought nor oversold. The STOCH value of 2.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZSTK.

ZeroStack Risk Analysis

ZeroStack disclosed 60 risk factors in its most recent earnings report. ZeroStack reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ZeroStack Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
$8.52M-0.36-44.42%-1.50%80.17%
46
Neutral
$17.56M-0.06-37.38%-22.60%53.82%
46
Neutral
$45.63M-5.00-130.42%-86.05%24.17%
40
Underperform
$3.79M-0.92-93.87%-0.74%81.49%
40
Underperform
$15.08M-0.57-63.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ZSTK
ZeroStack
7.22
-19.59
-73.06%
YCBD
cbdMD
0.81
-1.99
-71.00%
SXTC
China SXT Pharmaceuticals
2.24
-701.26
-99.68%
COSM
Cosmos Holdings
0.40
-0.12
-23.43%
IMCC
IM Cannabis Corp
0.72
-1.15
-61.44%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.82
-31.13
-89.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 28, 2026